EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature

Study Number:EA5163
IRB Number:1417269
Trial Type:Oncology - Pulmonary
Trial Status:Open to Accrual
Date Posted:03/29/2019
Principal Investigator:Mei Tang, MD
Contact Name:Kathryn Tower
Phone:443-849-3592
Fax:(443) 849-3777
Description:

For more information on this Clinical Trial, please visit the link below:

https://clinicaltrials.gov/ct2/show/NCT03793179?term=SIGNature-driven&cond=Lung+Cancer&rank=1

IMPORTANT Visitor Policy Changes

Recent Stories
|
Video
|
In the Media